
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter. BridgeBio Pharma collected $12.89 million in revenue during Q4, but reported earnings showed a $152.28 million loss.